PharVision Advisers’s Hamilton Lane HLNE Stock Holding History

PharVision Advisers’s Portfolio HLNE Stock Details HLNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,074	Closed	-$279K	–	344
2025 Q4	$279K	Buy	+2,074	New	+$261K	0.14%	320

Other funds holding HLNE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PharVision Advisers's HLNE Position: Q1 2026 in Review

PharVision Advisers sold out of Hamilton Lane (HLNE) in Q1 2026, closing a stake of 2,074 shares — an estimated $279K sold.

PharVision Advisers first reported a position in HLNE in Q4 2025 and held it in 1 quarter. The position peaked at $279K in Q4 2025. 388 funds tracked by Wall St. Rank hold HLNE as of Q1 2026.

PharVision Advisers reported no remaining Hamilton Lane position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 2,074 Hamilton Lane shares in Q1 2026, an estimated $279K.
PharVision Advisers first reported a position in Hamilton Lane in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Hamilton Lane position peaked at $279K in Q4 2025.
388 funds tracked by Wall St. Rank held Hamilton Lane as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.